Your browser doesn't support javascript.
loading
Physicochemical Stability Study of the Morphine-Bupivacaine-Ziconotide Association.
Sorrieul, Jeremy; Robert, Julien; Blanchet, Auriane; Gouju, Julien; Bienfait, Florent; Hamon, Sabrina Jubier; Dupoiron, Denis; Devys, Catherine.
Afiliação
  • Sorrieul J; Pharmacy, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France. Electronic address: jeremy.sorrieul@ico.unicancer.fr.
  • Robert J; Pharmacy, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Blanchet A; Pharmacy, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Gouju J; Pharmacy, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Bienfait F; Anesthesia and Pain Department, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Hamon SJ; Anesthesia and Pain Department, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Dupoiron D; Anesthesia and Pain Department, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
  • Devys C; Pharmacy, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.
Neuromodulation ; 2024 Jan 31.
Article em En | MEDLINE | ID: mdl-38300172
ABSTRACT

OBJECTIVE:

The aim of this study was to investigate the physicochemical stability of morphine-bupivacaine-ziconotide mixtures used in intrathecal analgesia in polypropylene syringes and intrathecal pumps. MATERIALS AND

METHODS:

The stability study method was conceived according to International Council for Harmonisation guidelines. For propylene syringes, six different mixtures of morphine-bupivacaine and ziconotide were assessed over seven days. Two storage temperatures were tested (5 °C ± 3 °C and 25 °C ± 2 °C). For implantable pumps, nine different mixtures were assessed over 60 days and stored at 37 °C. Assays were performed using ultrahigh-pressure liquid chromatography. Turbidity and pH also were measured throughout the study.

RESULTS:

Results confirmed excellent physicochemical stability for morphine and bupivacaine in the study for all conditions investigated (pumps at 37 °C, polypropylene syringes at 5 °C ± 3 °C and 25 °C ± 2 °C). Concerning ziconotide, after seven days, our study showed that every 95% confidence interval calculated had lower bounds >90% for all mixtures stored in polypropylene syringes. In implantable pumps, a decrease of the concentration was observed in all the mixtures studied. Moreover, the appearance of a degradation product confirmed the ziconotide degradation.

CONCLUSION:

All results are in favor with a physicochemical stable preparation for six mixture profiles when stored in polypropylene syringes at 5 °C ± 3 °C and 25 °C ± 2 °C. For mixtures stored in implantable pumps, the efficacy should decrease over time owing to the degradation of ziconotide. A trade-off between high morphine concentration and increased refill interval will need to be found by clinicians.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article